FAQ on Roth Capital Partners' Role in CapsoVision's $27.5 Million IPO

What was Roth Capital Partners’ role in CapsoVision’s IPO?

Roth Capital Partners served as the joint book-running manager for CapsoVision’s initial public offering, facilitating the sale of 5,500,000 shares at $5.00 per share, totaling approximately $27.5 million in gross proceeds.

When did CapsoVision’s shares start trading on the Nasdaq Capital Market?

CapsoVision’s shares began trading on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol ‘CV’.

What does CapsoVision specialize in?

CapsoVision is a commercial-stage medical technology company focused on AI-powered capsule endoscopy solutions.

How much did CapsoVision raise in its IPO?

CapsoVision raised approximately $27.5 million in gross proceeds from its IPO, before deductions.

What option was granted to the underwriters of CapsoVision’s IPO?

The underwriters were granted a 30-day option to purchase up to an additional 825,000 shares at the IPO price.

Where can I find more information about Roth Capital Partners?

More information about Roth Capital Partners can be found on their website at www.roth.com.

Where can I view the announcement of CapsoVision’s IPO?

The announcement of CapsoVision’s IPO can be viewed at https://ibn.fm/D3xFn.

What services does Roth Capital Partners offer?

Roth Capital Partners offers a full service platform including capital raising, equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access.

What is InvestorWire and how does it relate to this announcement?

InvestorWire is a specialized communications platform that provided the press release syndication for CapsoVision’s IPO announcement, part of the Dynamic Brand Portfolio @ IBN, focusing on reaching a wide audience of investors and the general public.